6033 Background: Cancer is a frequent complication of HIV infection.HAART has been widely used and has a positive impact on survival of AIDS, however its impact on incidence and survival of cancer in HIV patients is still unclear. Method: We performed a retrospective analysis of clinical data of HIV patients diagnosed in Hospital Nacional Guillermo Almenara Lima-Peru, collected from Jan 1992 to December 2002. 2422 HIV-seropositive patients were analized, representing 8738 person-years. HAART was introduced in our institution since 1998. Incidence was calculated as number of cases per 1000 person/year Results: During this 11 years observation period, 101 newly diagnosed cases of cancer were reported. The cancer incidence in the pre HAART period (1992–1997) was 19.87 compared with 8.56 (p<0.001) in post HAART era. Kaposi’s sarcoma incidence declined from 8.21 to 3.89 (p=0.012), also Non Hodgkin Lymphoma (NHL) incidence was significant lower after HAART use from 8.64 to 1.86 (p<0.001) as well as in Cerebral Lymphoma (3.02 to 0.15; p<0.001). No significant changes were observed in cervical or other tumors. Median overall survival of cancer patients with no HAART was 2 months compared with non reached median survival of HAART treated cancer patients, and the 5 years survival was 17% versus 61%(p<0.001).A superior 5 years survival for patients with HAART and antitumor therapy in comparison with cancer patients with HAART and no cancer treatment was also observed (70% vs 51% p<0.033). Conclusions: In our serie, incorporation of HAART as standard treatment in HIV patients produced a reduction in the incidence of Kaposi’ Sarcoma and NHL. We also observed an improvement in 5 years survival in patients diagnosed of HIV and cancer, treated with HAART, with or without the use of antineoplastic treatment. Our data demonstrated the benefit of using an aggressive treatment of HIV infection as well as for the cancer in the outcome of these patients. No significant financial relationships to disclose.